2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

2:30PM-4:00PM: Abstract Number: 2769

Predictive Value of Leisure-Time Physical Activity in Women with Systemic Erythematosus Lupus on Physical and Mental Health

ARHP Rehabilitation Science

2:30PM-4:00PM: Abstract Number: 2803

Predictors of Remission Maintenance up to Week 68 and Successful Therapy Discontinuation in Patients with Non-Radiographic Axial Spondyloarthritis Who Achieved Sustained Remission on 28-Week Open-Label Adalimumab Treatment

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III

2:30PM-4:00PM: Abstract Number: 2780

Preference Phenotypes Can be Used to Support Shared Decision Making at the Point-of-Care

Patient Outcomes, Preferences, and Attitudes II

2:30PM-4:00PM: Abstract Number: 2804

Pregnancy Outcomes in Patients with Ankylosing Spondylitis: A Nationwide Population Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III

2:30PM-4:00PM: Abstract Number: 2778

Preventing Rheumatoid Arthritis: North American Perspectives of Patients and First-Degree Relatives on the Risk of Developing the Disease and of Potential Preventative Interventions

Patient Outcomes, Preferences, and Attitudes II

2:30PM-4:00PM: Abstract Number: 2791

Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Marginal Jawbone Loss Predates the Onset of Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2790

Regulation of ASK1 Expression and Its Role in Rheumatoid Arthritis (RA)

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2785

Serious Infections Associated with Tofacitinib in Rheumatoid Arthritis Patients Previously Treated with Methotrexate

Rheumatoid Arthritis – Clinical Aspects IV: Medications and Risk

2:30PM-4:00PM: Abstract Number: 2773

Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2809

Spatial Navigation Impairment Associated with Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Neuropsychiatric Disease and Health Economics

2:30PM-4:00PM: Abstract Number: 2762

Study of 60 Patients with Intrauterine Fetal Deaths Related to Antiphospholipid Syndrome

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 2802

Sustained Remission of Inflammation Is Associated with Reduced Structural Damage on SI Joint MRI in Patients with Early Axial Spa: Evidence to Support the Concept of Treat-to-Target

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment III

2:30PM-4:00PM: Abstract Number: 2792

Th22 Cells Are a Potent Inducer of Osteoclastogenesis in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 2810

The Impact of Psychiatric Comorbidity on Health Care Utilization for Youth with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Neuropsychiatric Disease and Health Economics

2:30PM-4:00PM: Abstract Number: 2779

The Patient Perspective on Bdmard Dose Reduction: A Mixed Methods Study

Patient Outcomes, Preferences, and Attitudes II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].